Emily Howard

Emily provides patent advice in a range of biological areas, including cancer biology, vaccines, induced pluripotent stem cells, regenerative medicine, molecular biology and gene therapy.

Emily is particularly experienced in handling portfolios for small to medium sized UK-based companies. She devotes significant amounts of time to the development of IP strategies for such companies. She has worked closely with in-house counsel on both strategic and practical matters, including determining the best use of resources.  She has helped devise strategies relating to the filing and prosecution of applications across multiple jurisdictions.  

Emily is very knowledgeable in relation to freedom to operate (FTO) matters and has been heavily involved in developing strategies for FTO analysis.  She also has considerable experience in drafting and has drafted multi-disciplinary cases, such as applications which relate to both DNA constructs and lipid assemblies, thereby crossing the fields of chemistry and biotechnology.

Emily has handled a considerable amount of prosecution work for both Japanese and US companies, including large multinationals. She has been involved in successfully defending a number of European patents during opposition proceedings.

Prior to joining J A Kemp, Emily studied Natural Sciences at Cambridge University.  Her studies focussed on pathology, in particular microbiology and cancer biology, where she was awarded the Project Prize in cellular and genetic pathology.  She went on to complete a PhD in pathology at Cambridge University.  Her PhD focused on human papillomavirus (HPV), which causes cervical cancer.  Her work crossed the fields of cancer biology, innate immunology and virology as she investigated how HPV evades innate immune detection.

Emily joined J A Kemp in 2011 and became an associate in 2018.